A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Eisai

Status: Enrolling

Conditions: Alzheimer's Disease

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT06322667

BAN2401-J081-401

Details and patient eligibility

About

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.

Enrollment: 5,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All participants who are treated with lecanemab in routine clinical practice

Exclusion criteria

• None

Trial design

5,000 participants in 1 patient group

All Participants

Description:

Participants prescribed lecanemab by a physician in routine clinical practice (post-marketing surveillance) will be observed prospectively for up to a maximum of 156 weeks or to the time of discontinuation, whichever occurs first.

Treatment:

Other: No Intervention